Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
The journal adheres to the guidelines and best practices published by professional organizations, including ICMJE Recommendations and the Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by the Committee on Publication Ethics, COPE; the Directory of Open Access Journals; the World Association of Medical Editors; and Open Access Scholarly Publishers Association (https://doaj.org/bestpractice). Furthermore, the full process of handling research and publication misconduct should follow the COPE flowchart (https://publicationethics.org/resources/flowcharts).
Authors are responsible for the whole content of each
article. Co-authorship should be based on the following 4
(1) substantial contributions to the conception or
designing of the work; or the acquisition, analysis, or interpretation of data for the work;
(2) drafting or revising of the work critically for important intellectual content;
(3) final approval of the version to be published; and
(4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Any persons who do not meet the four criteria above should be placed as additional contributors in Acknowledgments section. The contributions of all authors must be described.
Ann Liver Transplant has adopted the CRediT Taxonomy (https://casrai.org/credit/) to describe each author’s individual contributions to the work. The role of each author and ORCID number should be addressed in the title page.
All submitted manuscripts should be original and should not be under consideration by other scientific journals for publication at the same time. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the editorial board. If a duplicate publication related to the papers of this journal is detected, the violation will be announced in the journal, their institutes will be informed, and the authors will be penalized.
The author is responsible for disclosing any financial support or benefit that might affect the content of the manuscript or might cause a conflict of interest. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.
Clinical research should be conducted in accordance
with the World Medical Association Declaration of Helsinki:
Medical Research Involving Human Subjects (https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/). Clinical studies that do not meet the Helsinki Declaration will not be considered for publication. Human subjects should not be identifiable, such that patients’ names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. For all clinical transplant investigation, authors should state their adherence to the Declaration of Istanbul. For animal subjects, research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.
Copies of written informed consent and Institutional Review Board (IRB)/Institutional Animal Care and Use Committee (IACUC) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB/ IACUC approval and study conduct.
When the journal faces suspected cases of research and publication misconduct such as duplicate publication, plagiarism, fraudulent or fabricated data, changes in authorship, undisclosed conflict of interest, ethical problem with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and etc., the resolving process will follow the flowchart provided by the COPE (https://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are done by the editorial board.
The editorial board will continuously work for monitoring/safeguarding publication ethics:
guidelines for retracting articles; maintenance of the integrity of the academic record;
preclusion of business needs from compromising intellectual and ethical standard; publishing corrections, clarifications, retractions and apologies when needed; no plagiarism, no fraudulent data. The editorial board checks manuscripts to confirm the originality of the text through Similarity Check. If the value of similarity index is unexpectedly high, it will be screened more precisely on plagiarism or duplicate publication.
Editors are always keeping the following responsibilities:
responsibility and authority to reject/accept article; no conflict of interest with respect to articles they reject/accept; acceptance of a paper only when reasonably certain; promotion of correction or retraction publication when errors are found; preservation of anonymity of the reviewers.
Ann Liver Transplant 2022; 2(1): 56-63
Ann Liver Transplant 2022; 2(1): 69-77
Ann Liver Transplant 2022; 2(1): 34-42